Suresh Giri

838 total citations
25 papers, 658 citations indexed

About

Suresh Giri is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Epidemiology. According to data from OpenAlex, Suresh Giri has authored 25 papers receiving a total of 658 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Epidemiology. Recurrent topics in Suresh Giri's work include Peroxisome Proliferator-Activated Receptors (12 papers), Diabetes Treatment and Management (7 papers) and Liver Disease Diagnosis and Treatment (6 papers). Suresh Giri is often cited by papers focused on Peroxisome Proliferator-Activated Receptors (12 papers), Diabetes Treatment and Management (7 papers) and Liver Disease Diagnosis and Treatment (6 papers). Suresh Giri collaborates with scholars based in India, United States and Israel. Suresh Giri's co-authors include Mukul R. Jain, Sib Sankar Roy, Nabanita Das, Pankaj Patel, Ramchandra Ranvir, Chitrang Trivedi, Akshyaya Rath, Ashok Mandala, Rüssel J. Reiter and Debasish Bandyopadhyay and has published in prestigious journals such as Diabetes, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Suresh Giri

24 papers receiving 648 citations

Peers

Suresh Giri
Praveen Kusumanchi United States
Yajun Zhou China
Xuping Yang China
Raina M. Rigoli United States
Maria D. Ybanez United States
Younis Hazari Chile
Shoichi Kanda Japan
Hiroyasu Hirose Japan
Shimaa M. Elshazly Egypt
Chengyong Tang China
Praveen Kusumanchi United States
Suresh Giri
Citations per year, relative to Suresh Giri Suresh Giri (= 1×) peers Praveen Kusumanchi

Countries citing papers authored by Suresh Giri

Since Specialization
Citations

This map shows the geographic impact of Suresh Giri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suresh Giri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suresh Giri more than expected).

Fields of papers citing papers by Suresh Giri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suresh Giri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suresh Giri. The network helps show where Suresh Giri may publish in the future.

Co-authorship network of co-authors of Suresh Giri

This figure shows the co-authorship network connecting the top 25 collaborators of Suresh Giri. A scholar is included among the top collaborators of Suresh Giri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suresh Giri. Suresh Giri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Giri, Suresh, Akshyaya Rath, Chitrang Trivedi, et al.. (2025). Peptide-Based Anti-PCSK9 Product for Long-Lasting Management of Hypercholesterolemia. Vaccines. 13(9). 889–889.
2.
Jain, Mukul R., Suresh Giri, Chitrang Trivedi, et al.. (2025). Discovery of ZYDG2: A potent, selective, and safe GPR40 agonist for treatment of type 2 diabetes. Journal of Pharmacology and Experimental Therapeutics. 392(4). 103534–103534. 1 indexed citations
3.
Giri, Suresh, et al.. (2023). Unraveling the Potential Role of Tecomella undulata in Experimental NASH. International Journal of Molecular Sciences. 24(4). 3244–3244. 5 indexed citations
4.
5.
Pola, Suresh, Shailesh R. Shah, Debdutta Bandyopadhyay, et al.. (2021). Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry. 35. 116071–116071. 12 indexed citations
6.
Yadav, Pragya D., Sanjeev Kumar Mendiratta, Sreelekshmy Mohandas, et al.. (2021). ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection. Viruses. 13(12). 2424–2424. 4 indexed citations
7.
Kumar, Divya P., Rebecca Caffrey, Jonathon Marioneaux, et al.. (2020). The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. Scientific Reports. 10(1). 9330–9330. 94 indexed citations
8.
Giri, Suresh, et al.. (2020). Authentication method to secure cloud data centres using biometric technology. 1–9. 3 indexed citations
9.
Agarwal, Sameer, Jeevan Kumar, Prashant Deshmukh, et al.. (2018). Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 28(10). 1849–1852. 14 indexed citations
10.
Caffrey, Rebecca, Jonathon Marioneaux, Prasanna K. Santhekadur, et al.. (2018). Saroglitazar treatment prevents NASH, eliminates hepatocyte ballooning, and significantly improves serum LFTs, lipids and insulin resistance in DIAMOND(tm) mice compared to pioglitazone benchmark. Journal of Hepatology. 68. S578–S579. 4 indexed citations
11.
12.
Agarwal, Sameer, Prashant Deshmukh, Debdutta Bandyopadhyay, et al.. (2016). Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist. ACS Medicinal Chemistry Letters. 7(12). 1134–1138. 8 indexed citations
13.
Jain, Mukul R., Suresh Giri, Chitrang Trivedi, et al.. (2015). Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid‐lowering and insulin‐sensitizing effects in preclinical models. Pharmacology Research & Perspectives. 3(3). 73 indexed citations
14.
15.
Shah, Shailesh R., Suresh Pola, Priyanka Priyadarshini, et al.. (2010). Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification. Bioorganic & Medicinal Chemistry Letters. 21(2). 628–632. 7 indexed citations
16.
Shah, Shailesh R., Suresh Pola, Priyanka Priyadarshini, et al.. (2010). Effect of structurally constrained oxime–ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists. Bioorganic & Medicinal Chemistry. 19(2). 771–782. 13 indexed citations
17.
Bhavsar, Shefalee K., et al.. (2009). Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression. Journal of Ethnopharmacology. 124(3). 426–433. 36 indexed citations
18.
Jain, Mukul R., Shailesh R. Shah, Suresh Pola, et al.. (2009). Design and synthesis of novel bis-oximinoalkanoic acids as potent PPARα agonists. Bioorganic & Medicinal Chemistry Letters. 20(3). 1156–1161. 3 indexed citations
19.
Jain, Mukul R., Shailesh R. Shah, Ashish Goel, et al.. (2008). Design and synthesis of novel oxazole containing 1,3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists. Bioorganic & Medicinal Chemistry. 16(15). 7117–7127. 15 indexed citations
20.
Jain, Mukul R., Shailesh R. Shah, Pravin Patil, et al.. (2008). Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. Bioorganic & Medicinal Chemistry Letters. 18(20). 5586–5590. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Praveen Kusumanchi Breakdown of academic impact, for papers by Yajun Zhou Breakdown of academic impact, for papers by Xuping Yang Breakdown of academic impact, for papers by Raina M. Rigoli Breakdown of academic impact, for papers by Maria D. Ybanez Breakdown of academic impact, for papers by Younis Hazari Breakdown of academic impact, for papers by Shoichi Kanda Breakdown of academic impact, for papers by Hiroyasu Hirose Breakdown of academic impact, for papers by Shimaa M. Elshazly Breakdown of academic impact, for papers by Chengyong Tang
Rankless by CCL
2026